Thursday, April 27

  Plenary: Can We Afford Innovation in Oncology?
  Paul Cornes, Clinical Outcomes Group, Bristol, United Kingdom

  Clinical 1
  Immune Related Adverse
  Effect Management

  Alexandre Chan, National
  University of Singapore,
  Singapore

  Fundamentals 1
  Technology Updates

  Jennifer Jupp, Alberta
  Health Services - Calgary
  Zone, Calgary, Canada

  Felice Musicco, Instituti
  Fisioterapici Ospitalieri,
  Rome, Italy

  Research 1
  Workplace Contamination
  Update

  Rudolf Schierl, Institute for
  Occupational, Social and
  Environmental Medicine,
  University Hospital Munich,
  Munich, Germany

  Clinical 2
  Solid Tumour Updates

  Peter Gilbar, Toowoomba
  Hospital, Toowoomba,
  Australia

  Evelyn Handel, National
  Comprehensive Cancer
  Network, Willow Grove,
  USA

  Gábor Takács, Budapest,
  Hungary

  Fundamentals 2
  Safety of Monoclonal
  Antibodies

  Marliese Alexander, Peter
  MacCallum Cancer
  Centre, Melbourne,
  Australia

  Tiene Bauters, Ghent
  University Hospital,
  Ghent, Belgium

  Research 2
  Integration of Research into
  Daily Practice

  Alain Astier, Henri Mondor
  University Hospital Group,
  Paris, France

  Lisa Holle, University of
  Connecticut, Storrs, USA

  Clinical 3
  Pediatric/Adolescent/Young
  Adult Case Discussions

  Tiene Bauters, Ghent
  University Hospital,
  Ghent, Belgium

  Jennifer Jupp, Alberta
  Health Services - Calgary
  Zone, Calgary, Canada

  Rosalyn Sims, Children’s
  Hospital of Michigan,
  Michigan, USA

  John Wiernikowski,
  McMaster Children’s
  Hospital, Hamilton,
   Canada

  Fundamentals 3
  Biosimilars - Panel

  Barbara Claus, Ghent,
  University Hospital,
  Ghent, Belgium

  Paul Cornes, Clinical
  Outcomes Group, Bristol,
  United Kingdom

  Sandor Kerpel-Fronius,
  Semmelweis Medical
  University, Budapest,
  Hungary

  Research 3
  Investigational Agents Update

  Rowena Schwartz, James L.
  Winkle College of Pharmacy
  University of Cincinnati
  Cincinnati, USA

  Ida Homoki,National Institute
  of Oncology, Budapest,
  Hungary

Friday, April 28

  ISOPP Awards Presentation
  Harbans Dhillon, ISOPP President, Kuala Lumpur, Malaysia  

  Plenary: Ethical and Legal Aspects of Physician Assisted Dying and the Pharmacist’s Role
  Ulrich Schuler, Universitätsklinikum Carl Gustav Carus, Dresden, Germany

  Clinical 4
  Cancer Associated
  Thrombosis - Clinical
  Considerations and Tools
  For the Oncology
  Pharmacist

  Marliese Alexander, Peter
  MacCallum Cancer
  Centre, Melbourne,
  Australia

  Fundamentals 4
  The Role of the Pharmacist
  in the Management of Oral
  Chemotherapy: From 
  Theory to Practice

  Fabrizio Festinese, ASST
  Lodi, Lodi, Italy
  

  Research 4
  Collaborating with the
  Pharmaceutical Industry to
  Help Reduce the Cost of
  Cancer Drugs

  Carole Chambers, Alberta
  Health Services Cancer Care,
  Calgary, Canada

  Peter Gilbar, Toowoomba
  Hospital, Toowoomba,
  Australia

  Satellite Symposium - BD Medical
  Safe Handling of Hazardous Drugs: A Global Perspective

  Clinical 5
  Hematology Updates

  Donald Harvey, Winship
  Cancer Institute of Emory
  University, Atlanta, USA

  Tara Leslie, Alberta
  Health Services/
  University of Alberta,
  Calgary, Canada

  Fundamentals 5
  Basics of Best Practice

  Lisa Holle, University of
  Connecticut, Storrs, USA

  Birgit Tans, UZ Leuven,
  Belgium

  Research 5
  Platform Presentations

  Eskinder Eshetu Ali and Lita
  Chew, Singapore, Singapore

  Tine Van Nieuwenhuyse and
  Brigit Tans, Leuven, Belgium

  Phebe Si, Singapore, 
  Singapore

  Chenchia Lin, Taipei City,
  Taiwan

  Matteo Federici, Mainz, 
  Germany

Saturday, April 29

  Plenary: Platform Presentations

• Lisa Holle, Storrs, USA
• Lauren Charbonneau, Toronto, Canada 
• Sulamita Miranda Nam, Santiago, Chile
• Shinya Suzuki, Kashiwa, Japan

  Clinical 6
  Supportive Care
  Update: Pain Management

  Dezső Embey Isztin,
  National Oncology,
  Budapest, Hungary

  Fundamentals 6
  Appraisal and Funding of
  Cancer Drugs in England

  David Thomson, 
  Chemotherapy CRG and
  National Cancer Drug
  Fund, NHS England,
  West Yorkshire, United
  Kingdom

  Research 6
  Side Effect Management on
  Immune-Oncology Agents

  Bruce Burnett, University
  of Central Lancashire, 
  Preston, United Kingdom

  Satellite Symposium - Jazz Pharmaceuticals
  A Pharmacy Perspective on Post-HSCT Complications, with a Focus on VOD

  Clinical 7
  BMT Updates

  Tiene Bauters, Ghent
  University Hospital,
  Ghent, Belgium

  Jennifer Jupp, Alberta
  Health Services - Calgary
  Zone, Calgary, Canada

  Fundamentals 7
  Stability of Cancer Agents

  Alain Astier, Henri Mondor
  University Hospital Group,
  Paris, France

  Johan Vandenbroucke,
  Ghent University Hospital,
  Ghent, Belgium

  Research 7
  Research into Oral
  Chemotherapy Management
  Programs

  Fabrizio Festinese, ASST 
  Lodi, Lodi, Italy

  Lisa Holle, University of
  Connecticut, Storrs, USA

  Shinya Suzuki, National
  Cancer Center Hospital East,
  Kashiwa, Japan

  Closing Panel: Dollars and Sense

  Barbara Claus, Ghent, University Hospital, Ghent, Belgium
  Harbans Dhillon, Kuala Lumpur, Malaysia
  Shaun O'Connor, Eastern Health, Melbourne, Australia
  Rowena Schwartz, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, USA
  Shinya Suzuki, Pharmacist, National Cancer Center Hospital East, Kashiwa, Japan
  David Thomson,Chemotherapy CRG and National Cancer Drugs Fund, NHS England, West
  Yorkshire, United Kingdom

  Moderator: Carole Chambers, Pharmacy Director, Alberta Health and Services Cancer Care,
  Calgary, Canada

  Awards and Closing Remarks
  Harbans Dhillon, ISOPP President, Kuala Lumpur, Malaysia